A brand new meta-analysis combining 22 research, to be offered on the Annual Assembly of the European Affiliation for the Research of Diabetes (EASD) in Hamburg, Germany (2–6 October), reveals that tirzepatide is superior to semaglutide for each management of blood sugar and when it comes to quantity of physique weight misplaced by sufferers. The examine is by Dr. Thomas Karagiannis, Aristotle College of Thessaloniki, Thessaloniki, Greece, and colleagues.
Semaglutide is permitted for therapy of kind 2 diabetes and likewise weight problems/weight reduction administration. Tirzepatide has been permitted for treating kind 2 diabetes and its producers have submitted functions for its approval for weight problems/weight reduction administration.
There are few randomized managed trials (RCTs) straight evaluating subcutaneous tirzepatide with subcutaneous semaglutide. On this new analysis, the authors mixed the information from 22 out there trials to carry out a meta-analysis to match tirzepatide with semaglutide when it comes to their efficacy and security in folks with kind 2 diabetes.
The authors searched Medline and the Cochrane Library for RCTs that assessed a upkeep dose of subcutaneous tirzepatide 5, 10, or 15 mg once-weekly or subcutaneous semaglutide 0.5, 1.0, or 2.0 mg once-weekly for a minimum of 12 weeks.
Comparators had been any of the eligible doses of tirzepatide and semaglutide, placebo, and likewise different glucose-lowering medicine supplied they had been straight in comparison with tirzepatide and semaglutide in a minimum of one trial. The meta-analysis then calculated any variations in results on HbA1c (glycated hemoglobin, a measure of blood sugar management), physique weight, and likewise the chance of opposed occasions.
The 22 RCTs included information from 18,472 sufferers, all with a prognosis of kind 2 diabetes. The authors discovered that tirzepatide 15 mg was essentially the most efficacious in lowering HbA1c versus placebo (imply distinction -2.00%), adopted by tirzepatide 10 mg (-1.86%) and semaglutide 2.0 mg (-1.62%).
Every of the three tirzepatide doses decreased HbA1c greater than the respective low-, medium-, and high-dose of semaglutide. Versus placebo, tirzepatide was extra efficacious in lowering physique weight (-10.96 Kg, -8.75 Kg, and -6.16 Kg for tirzepatide 15, 10, and 5 mg respectively) than semaglutide (-5.24 Kg, -4.44 Kg, and -2.72 Kg for semaglutide 2.0, 1.0, and 0.5 mg respectively).
Concerning between-drug comparisons, each tirzepatide 10 and 15 mg had been extra efficacious in reducing physique weight versus semaglutide 0.5, 1.0, and a pair of.0 mg, whereas tirzepatide 5 mg was extra efficacious versus semaglutide 0.5 and 1.0 mg.
Though not within the journal summary, the authors have been capable of present outcomes for change in physique weight from the analyses evaluating tirzepatide and semaglutide (slightly than versus placebo). These numerical values might be offered within the oral presentation within the congress.
The precise variations in change in body weight (imply distinction) for the next comparisons are:
- Tirzepatide 15 mg versus semaglutide 2.0 mg = -5.72 Kg (i.e., a imply of 5.72 Kg extra weight misplaced in these taking tirzepatide 15 mg versus these taking semaglutide 2.0 mg)
- Tirzepatide 10 mg versus semaglutide 2.0 mg = -3.52 Kg
- Tirzepatide 5 mg versus semaglutide 1.0 mg = -1.72 Kg
The authors clarify, “In abstract the three tirzepaide doses had been more practical than the three respective semaglutide doses, with the distinction between the 2 medicine being bigger with the higher doses.”
As in comparison with placebo, all doses of tirzepatide and semaglutide elevated threat for gastrointestinal opposed occasions, with tirzepatide 15 mg yielding the very best elevated threat (3.6 occasions) for nausea, vomiting (4.4 occasions) and diarrhea (double the chance).
Between-drug comparisons yielded non-statistically important outcomes, aside from tirzepatide 15 mg versus semaglutide 1.0 mg (39% elevated vomiting threat) and 0.5 mg (85% elevated vomiting threat), and tirzepatide 15 mg versus semaglutide 0.5 mg (45% elevated threat of nausea). There was no distinction between tirzepatide, semaglutide and placebo concerning threat for severe opposed occasions.
The authors conclude, “In folks with kind 2 diabetes, tirzepatide 5, 10, and 15 mg had been extra efficacious in lowering HbA1c in comparison with semaglutide 0.5, 1.0, and a pair of.0 mg, respectively. Tirzepatide additionally was additionally more practical for weight reduction than semaglutide, with a bigger weight-loss impact at greater doses. Excessive-dose tirzepatide (15 mg) was related to elevated threat for vomiting versus low- and medium-dose semaglutide.”
Tirzepatide more practical in blood sugar management and physique weight reduction than semaglutide, reveals meta-analysis (2023, September 22)
retrieved 22 September 2023
This doc is topic to copyright. Aside from any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.